TY - JOUR
T1 - Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms
AU - Tamma, Pranita D.
AU - Hsu, Alice J.
N1 - Funding Information:
Financial support. This work was supported by funding from National Institutes of Health grant K23-AI127935 awarded to P. D. T. P. D. T. has received investigator-initiated research funding from Merck, with all work and funding completed in June 2018, and unrelated to this work.
Publisher Copyright:
© 2019 Oxford University Press. All rights reserved.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.
AB - With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.
KW - Aztreonam-avibactam
KW - Cefiderocol
KW - Ceftazidime-avibactam
KW - Ceftolozane-tazobactam
KW - Imipenem-cilastatin-relebactam
KW - Meropenem-vaborbactam
UR - http://www.scopus.com/inward/record.url?scp=85070683518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070683518&partnerID=8YFLogxK
U2 - 10.1093/jpids/piz002
DO - 10.1093/jpids/piz002
M3 - Review article
C2 - 30793757
AN - SCOPUS:85070683518
SN - 2048-7193
VL - 8
SP - 251
EP - 260
JO - Journal of the Pediatric Infectious Diseases Society
JF - Journal of the Pediatric Infectious Diseases Society
IS - 3
ER -